Editorial: Licensing and Use of New Therapies in MS: Where Are We Going?
Publication
, Journal Article
Hurwitz, B
Published in: Int MS J
August 2005
Duke Scholars
Published In
Int MS J
ISSN
1352-8963
Publication Date
August 2005
Volume
12
Issue
2
Start / End Page
39 / 41
Location
England
Related Subject Headings
- United States Food and Drug Administration
- United States
- Neurology & Neurosurgery
- Natalizumab
- Multiple Sclerosis
- Licensure
- Interferon-beta
- Interferon beta-1a
- Humans
- Health Services
Citation
APA
Chicago
ICMJE
MLA
NLM
Hurwitz, B. (2005). Editorial: Licensing and Use of New Therapies in MS: Where Are We Going? Int MS J, 12(2), 39–41.
Hurwitz, Barrie. “Editorial: Licensing and Use of New Therapies in MS: Where Are We Going?” Int MS J 12, no. 2 (August 2005): 39–41.
Hurwitz B. Editorial: Licensing and Use of New Therapies in MS: Where Are We Going? Int MS J. 2005 Aug;12(2):39–41.
Hurwitz, Barrie. “Editorial: Licensing and Use of New Therapies in MS: Where Are We Going?” Int MS J, vol. 12, no. 2, Aug. 2005, pp. 39–41.
Hurwitz B. Editorial: Licensing and Use of New Therapies in MS: Where Are We Going? Int MS J. 2005 Aug;12(2):39–41.
Published In
Int MS J
ISSN
1352-8963
Publication Date
August 2005
Volume
12
Issue
2
Start / End Page
39 / 41
Location
England
Related Subject Headings
- United States Food and Drug Administration
- United States
- Neurology & Neurosurgery
- Natalizumab
- Multiple Sclerosis
- Licensure
- Interferon-beta
- Interferon beta-1a
- Humans
- Health Services